116 related articles for article (PubMed ID: 26270899)
1. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.
Giri S; Bhatt VR; Pathak R; Bociek RG; Vose JM; Armitage JO
Am J Hematol; 2015 Nov; 90(11):1052-4. PubMed ID: 26270899
[TBL] [Abstract][Full Text] [Related]
2. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma.
Jackson MW; Rusthoven CG; Jones BL; Kamdar M; Rabinovitch R
Am J Hematol; 2016 May; 91(5):476-80. PubMed ID: 26852276
[TBL] [Abstract][Full Text] [Related]
3. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
5. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
7. Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis.
Jackson MW; Rusthoven CG; Jones BL; Kamdar M; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):126-132. PubMed ID: 26547384
[TBL] [Abstract][Full Text] [Related]
8. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis.
Haque W; Dabaja B; Tann A; Khan M; Szeja S; Butler EB; Teh BS
Radiother Oncol; 2016 Jul; 120(1):150-5. PubMed ID: 27373911
[TBL] [Abstract][Full Text] [Related]
9. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
11. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
12. Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis.
Jiang S; Zhen H; Jiang H
J Adolesc Young Adult Oncol; 2019 Oct; 8(5):623-627. PubMed ID: 31150309
[TBL] [Abstract][Full Text] [Related]
13. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
14. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
[TBL] [Abstract][Full Text] [Related]
15. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis.
Pugh TJ; Ballonoff A; Rusthoven KE; McCammon R; Kavanagh B; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):845-9. PubMed ID: 19515509
[TBL] [Abstract][Full Text] [Related]
16. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
19. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]